20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Monopar Therapeutics Inc (MNPR) operates in the BIOTECHNOLOGY industry and is headquartered in Wilmette, United States with about 22 employees. Its market capitalization is roughly $754 million. In the fiscal year ended 2025-12-31, MNPR reported $0M in revenue and ($14M) in net income.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($22M) | ($17M) | ($16M) | ($9M) | ($11M) | ($9M) | ($7M) | ($4M) | ($3M) | ($17M) | ($1M) | ($1M) |
| Operating Margin % | — | — | — | — | — | — | -5317.7% | — | — | — | — | — |
| Net Income | ($18M) | ($14M) | ($16M) | ($8M) | ($10M) | ($9M) | ($6M) | ($4M) | ($3M) | ($17M) | ($1M) | ($1M) |
| Net Margin % | — | — | — | — | — | — | -5150.8% | — | — | — | — | — |
| EBITDA | ($19M) | ($14M) | ($16M) | ($8M) | ($11M) | ($9M) | ($6M) | ($4M) | ($3M) | ($17M) | ($1M) | $0M |
| Earnings Per Share (EPS) | $-2.34 | $-1.85 | $-1.36 | $-0.58 | $-0.83 | $-0.73 | $-0.58 | $-0.39 | $-0.31 | $-1.59 | $-0.12 | $-0.12 |
| Shares Outstanding (M) | 9M | 7M | 11M | 15M | 13M | 12M | 11M | 11M | 10M | 10M | 10M | 8M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($7M) | ($5M) | ($6M) | ($4M) | ($3M) | ($3M) | ($11M) | ($2M) |
| Operating Margin % | — | — | — | — | — | — | — | — |
| Net Income | ($5M) | ($4M) | ($5M) | ($3M) | ($2M) | ($3M) | ($11M) | ($1M) |
| Net Margin % | — | — | — | — | — | — | — | — |
| EBITDA | ($5M) | ($4M) | ($5M) | ($4M) | ($2M) | ($3M) | ($11M) | ($1M) |
| Earnings Per Share (EPS) | $-0.62 | $-0.46 | $-0.78 | $-0.48 | $-0.35 | $-0.38 | $-0.95 | $-0.11 |
| Shares Outstanding (M) | 9M | 9M | 7M | 7M | 7M | 7M | 11M | 11M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($3.3B) | ($12M) | ($6M) | ($8M) | ($7M) | ($7M) | ($5M) | ($3M) | ($3M) | ($3M) | ($1M) | ($1M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($3.3B) | ($12M) | ($6M) | ($8M) | ($7M) | ($7M) | ($5M) | ($3M) | ($3M) | ($3M) | ($1M) | ($1M) |
| FCF Margin % | — | — | — | — | — | — | -3809.0% | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($3.2B) | ($3M) | ($3M) | ($2M) | ($1M) | ($6M) | ($2M) | ($1M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($3.2B) | ($3M) | ($3M) | ($2M) | ($1M) | ($6M) | ($2M) | ($1M) |
| FCF Margin % | — | — | — | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $135M | $141M | $60M | $7M | $13M | $21M | $17M | $13M | $7M | $10M | $3M | $3M |
| Cash & Cash Equivalents | $53M | $62M | $46M | $7M | $8M | $20M | $17M | $13M | $7M | $9M | $2M | $2M |
| Total Liabilities | $4M | $3M | $5M | $2M | $3M | $2M | $1M | $1M | $0M | $0M | $0M | $0M |
| Total Debt (Short + Long-Term) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Total Shareholders' Equity | $131M | $138M | $55M | $6M | $10M | $19M | $16M | $13M | $7M | $10M | $3M | $3M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive MNPR viewer.
About TickerBase · Data methodology & sources · Privacy · Terms